174 related articles for article (PubMed ID: 16922969)
1. Severe palmoplantar erythrodysesthesia and intertrigolike eruption induced by polyethylene glycol-coated liposomal doxorubicin.
Campanelli A; Kerl K; Lübbe J
J Eur Acad Dermatol Venereol; 2006 Sep; 20(8):1022-4. PubMed ID: 16922969
[No Abstract] [Full Text] [Related]
2. [Liposomal doxorubicin and palmoplantar erythrodysesthesia].
Tomb R; Stephan F; Halaby G
Ann Dermatol Venereol; 2003 Nov; 130(11):1057-8. PubMed ID: 14724543
[No Abstract] [Full Text] [Related]
3. Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome.
Mangana J; Zipser MC; Conrad C; Oberholzer PA; Cozzio A; Knuth A; French LE; Dummer R
Eur J Dermatol; 2008; 18(5):566-70. PubMed ID: 18693162
[TBL] [Abstract][Full Text] [Related]
4. Hand-foot syndrome.
Pike K
Oncol Nurs Forum; 2001; 28(10):1519-20. PubMed ID: 11759299
[No Abstract] [Full Text] [Related]
5. Histologic patterns of polyethylene glycol-liposomal doxorubicin-related cutaneous eruptions.
Cady FM; Kneuper-Hall R; Metcalf JS
Am J Dermatopathol; 2006 Apr; 28(2):168-72. PubMed ID: 16625083
[TBL] [Abstract][Full Text] [Related]
6. Distal phalange necrosis: a severe manifestation of palmar plantar erythrodysesthesia.
Palaia I; Angioli R; Bellati F; Basile S; Rabitti C; Panici PB
Am J Obstet Gynecol; 2006 Oct; 195(4):e1-2. PubMed ID: 16875651
[TBL] [Abstract][Full Text] [Related]
7. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced toxic erythema under treatment with pegylated liposomal doxorubicin: No restriction to palms and soles.
Ziemer M; Goetze S; Kaatz M; Elsner P
J Am Acad Dermatol; 2008 Feb; 58(2 Suppl):S44-6. PubMed ID: 18191705
[No Abstract] [Full Text] [Related]
9. Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin.
Gordinier ME; Dizon DS; Fleming EL; Weitzen S; Schwartz J; Parker LP; Granai CO
Gynecol Oncol; 2006 Oct; 103(1):72-4. PubMed ID: 16494932
[TBL] [Abstract][Full Text] [Related]
10. Case of severe bullous erythema including intertrigo-like eruptions with angioedema induced by pegylated liposomal doxorubicin.
Totsuka M; Watanabe Y; Asai C; Takahashi S; Ishikawa H; Takamura N; Hagiwara M; Aihara M
J Dermatol; 2019 Jun; 46(6):535-539. PubMed ID: 31021010
[TBL] [Abstract][Full Text] [Related]
11. An intertrigo-like eruption from pegylated liposomal doxorubicin.
Korver GE; Ronald H; Petersen MJ
J Drugs Dermatol; 2006 Oct; 5(9):901-2. PubMed ID: 17039658
[TBL] [Abstract][Full Text] [Related]
12. Intertrigo-like eruption caused by pegylated liposomal doxorubicin (PLD).
Sánchez Henarejos P; Ros Martínez S; Marín Zafra GR; Alonso Romero JL; Navarrete Montoya A
Clin Transl Oncol; 2009 Jul; 11(7):486-7. PubMed ID: 19574209
[TBL] [Abstract][Full Text] [Related]
13. "Skin problems associated with pegylated liposomal doxorubicin -- more than palmoplantar erythrodysesthesia syndrome".
Von Moos R; Cathomas R
Eur J Dermatol; 2009; 19(3):264-5. PubMed ID: 19213658
[No Abstract] [Full Text] [Related]
14. The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia.
Martschick A; Sehouli J; Patzelt A; Richter H; Jacobi U; Oskay-Ozcelik G; Sterry W; Lademann J
Anticancer Res; 2009 Jun; 29(6):2307-13. PubMed ID: 19528496
[TBL] [Abstract][Full Text] [Related]
15. Hand-foot syndrome related to liposomal doxorubicin.
Swenson KK; Bell EM
Oncol Nurs Forum; 2010 Mar; 37(2):137-9. PubMed ID: 20189920
[No Abstract] [Full Text] [Related]
16. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia.
Lopez AM; Wallace L; Dorr RT; Koff M; Hersh EM; Alberts DS
Cancer Chemother Pharmacol; 1999; 44(4):303-6. PubMed ID: 10447577
[TBL] [Abstract][Full Text] [Related]
17. Palmar-plantar erythrodysesthesia.
Wilkes GM; Doyle D
Clin J Oncol Nurs; 2005 Feb; 9(1):103-6. PubMed ID: 15751504
[No Abstract] [Full Text] [Related]
18. Striking follicular eruption to pegylated liposomal doxorubicin.
Dai J; Micheletti R; Rosenbach M; Chu EY
Am J Dermatopathol; 2014 Jul; 36(7):590-1. PubMed ID: 24614205
[TBL] [Abstract][Full Text] [Related]
19. Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin.
English JC; Toney R; Patterson JW
J Cutan Pathol; 2003 Oct; 30(9):591-5. PubMed ID: 14507411
[TBL] [Abstract][Full Text] [Related]
20. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin.
Lotem M; Hubert A; Lyass O; Goldenhersh MA; Ingber A; Peretz T; Gabizon A
Arch Dermatol; 2000 Dec; 136(12):1475-80. PubMed ID: 11115157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
